Literature DB >> 9796977

Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance.

H Lin1, M L Bondy, L A Langford, K R Hess, G L Delclos, X Wu, W Chan, M A Pershouse, W K Yung, P A Steck.   

Abstract

The frequency of loss of heterozygosity (LOH) around MMAC/PTEN and DMBT1 loci and survival analyses based on the LOH status were assessed in 110 patients with different histological groups of gliomas. Twenty-six of the patients had anaplastic oligodendrogliomas, 31 had anaplastic astrocytomas, and 53 had glioblastomas multiforme (GM). At the DMBT1 locus, LOH was observed very frequently in all three histological groups, with no significant difference in the frequency of LOH among the three histological groups. At the MMAC/PTEN locus, patients with GM exhibited a significantly increased frequency of LOH (72%) compared with patients with anaplastic astrocytomas (29%) or anaplastic oligodendrogliomas (31%) (P < 0.0001). Kaplan-Meier survival plots showed that patients with LOH at the MMAC/PTEN locus had a significantly worse prognosis than did patients without LOH at the MMAC/PTEN locus [hazard ratio (LOH versus non-LOH), 2.65; 95% confidence interval (CI), 1.69-4.46; P < 0.0001]. Cox proportional hazards regression analysis, adjusted for age at surgery and histological grades (GM and non-GM), showed that LOH at the MMAC/PTEN locus was a significant predictor of shorter survival [hazard ratio (LOH versus non-LOH), 2.01; 95% CI, 1.1-3.5; P = 0.018). Our analysis failed to indicate a similar association between the frequency of LOH at the DMBT1 locus and patient survival [hazard ratio (LOH versus non-LOH), 2; 95% CI, 0.37-3.13; P = 0.2]. These results suggest that the DMBT1 gene may be involved early in the oncogenesis of gliomas, whereas alterations in the MMAC/PTEN gene may be a late event in the oncogenesis related to progression of gliomas and provide a significant prognostic marker for patient survival.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796977

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

1.  Akt-mediated survival of oligodendrocytes induced by neuregulins.

Authors:  A I Flores; B S Mallon; T Matsui; W Ogawa; A Rosenzweig; T Okamoto; W B Macklin
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Identification of uncommon chromosomal aberrations in the neuroglioma cell line H4 by spectral karyotyping.

Authors:  D Krex; B Mohr; M Hauses; G Ehninger; H K Schackert; G Schackert
Journal:  J Neurooncol       Date:  2001-04       Impact factor: 4.130

3.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.

Authors:  H Sasaki; M C Zlatescu; R A Betensky; Y Ino; J G Cairncross; D N Louis
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 4.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

5.  Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area.

Authors:  Margaret Wrensch; Terri Rice; Rei Miike; Alex McMillan; Kathleen R Lamborn; Kenneth Aldape; Michael D Prados
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

6.  Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas.

Authors:  Kinya Terada; Takashi Tamiya; Shigeru Daido; Hirokazu Kambara; Hiroaki Tanaka; Yasuhiro Ono; Kengo Matsumoto; Sachio Ito; Mamoru Ouchida; Takashi Ohmoto; Kenji Shimizu
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

Review 7.  Genes and pathways driving glioblastomas in humans and murine disease models.

Authors:  Adrian Merlo
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

8.  Assessment of genetic markers and glioblastoma stem-like cells in activation of dendritic cells.

Authors:  Aysel Yurtsever; Ayfer Haydaroglu; Cigir Biray Avci; Cumhur Gunduz; Nezih Oktar; Tayfun Dalbasti; Hasan Onur Caglar; Rukset Attar; Gul Kitapcioglu
Journal:  Hum Cell       Date:  2013-06-05       Impact factor: 4.174

9.  Tyrosine kinase expression in pediatric high grade astrocytoma.

Authors:  Muh-Lii Liang; Jing Ma; Michael Ho; Lauren Solomon; Eric Bouffet; James T Rutka; Cynthia Hawkins
Journal:  J Neurooncol       Date:  2008-01-10       Impact factor: 4.130

10.  Immunohistochemical markers for prognosis of anaplastic astrocytomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.